Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

30/07/2014 Barcelona among the top 10 cities in the world 24/07/2014 Researchers prove the effectiveness of a new drug against malaria using synchrotron light 17/07/2014 Creation of the Health Technologies Cluster 10/07/2014 An international team of scientists led by researchers from the UAB creates the world's first magnetic hose 03/07/2014 CaixaBank and Oracle set up a Big Data Centre of Excellence in the Barcelona Synchrotron Park 26/06/2014 The Barcelona Supercomputing Center hosts two important new international projects
39 40 41 42 43 44 45 46 47 48 49